In this online, self-learning activity:
Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia B is the same in all geographic regions, populations, and ethnic groups, affecting approximately 1 out of every 30,000 male births. The condition is diagnosed by measuring FIX activity, and patients with severe hemophilia have levels of 1% or less.
Patients with severe hemophilia B are at risk for spontaneous, life-threatening bleeding episodes. Untreated, the life expectancy is approximately 20 years, and painful or even life-threatening morbidities include intracranial hemorrhage, severe bleeding in other organ systems, musculoskeletal injury, and joint injury. In contrast, in people with moderate or mild hemophilia, abnormal bleeding usually occurs after minor trauma or surgery.
This is a learning activity focused on Hemophilia B and its complications, designed to bring healthcare providers up to date in their practice and give them a sense of coming changes to practice and the literature.
The following healthcare professionals: hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with hemophilia B.
This program is supported by an educational grant from Shire.
Release Date: March 05, 2019 -- Expiration Date: March 05, 2021
Faculty: Christopher Walsh, MD
Faculty member introduction, disclosures, overview of Hemophilia B
Major findings from ASH 2018, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content)
Applicability to clinical practice and patient cases, where relevant
By the end of the session the participant will be able to:
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dr. Christopher Walsh, MD, PhD, Mount Sinai School of Medicine, New York, NY has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Shire.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Hemophilia A: Optimizing Pharmacotherapeutic Management Strategies
von Willebrand's disease (vWD): therapeutic updates and optimizing treatment
Contemporary approaches to advanced diffuse large B-cell lymphoma (DLBCL)
Congenital Thrombotic Thrombocytopenic Purpura (cTTP): Updates from the American Society of Hematology (ASH) 2019 annual meeting